Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)
DiscussionThe demonstration that bisoprolol reduces the incidence of exacerbations would be relevant not only to patients and clinicians but also to healthcare providers, in the UK and globally.Trial registrationCurrent controlled trialsISRCTN10497306. Registered on 16 August 2018 (Source: Trials)
Source: Trials - April 14, 2022 Category: Research Source Type: clinical trials
Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease
Conditions: Coronary Microvascular Dysfunction; Microvascular Angina; Vasospasm, Coronary; Vasospastic Angina; Prinzmetal Angina; Coronary Artery Disease Interventions: Drug: Bisoprolol; Drug: Diltiazem; Drug: Placebo Sponsors: Charite University, Berlin, Germany; Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 24, 2022 Category: Research Source Type: clinical trials
